Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and Project Orbis. Writing in the September 2026 edition of DIA Global Forum, Sandy Chan, Sok Bee Lim, Shirley Yong, and Helene Sou of the Singapore Association of Pharmaceutical Industries unpack how sustained industry-regulator collaboration got it there, and what it means for the next wave of gene therapies and AI-enabled devices.
Over the past two and a half decades, HSA has continuously evolved its regulatory framework to remain agile, science-based, and fit for purpose in response to advances in science in a rapidly changing healthcare landscape. In 2025, SAPI conducted a confidential, members-only survey to better understand the key factors within Singapore’s environment that have influenced patient access over the previous five years. The survey identified HSA’s regulatory predictability, reliance/collaborative pathways, streamlined dossier requirements, and efficient review timelines as key contributors to improving patient access to innovative therapies in Singapore. Today, HSA’s regulatory system is internationally recognized for its scientific rigor, agility, and commitment to advancing public health.
A Modern, Risk-Based Regulatory System
From the Singapore-based industry perspective, the past decade (2016-2026) has been particularly significant, marked by regulatory innovation, international collaboration, and close regulator-industry engagement that have supported timely access to innovative health products.
While Singapore is a relatively small domestic market, it serves as a leading regional hub for pharmaceuticals, biotechnology, and medical technology. More than 60 biopharmaceutical manufacturing facilities operate in Singapore, producing a broad range of products, including active pharmaceutical ingredients, biologics, cell therapies, and antibody-drug conjugates. With biopharmaceutical industry output exceeding S$18 billion in 2023, Singapore has developed a strong ecosystem that supports close regulator-industry collaboration and regulatory innovation. Consistent with this environment, Singapore’s regulatory environment for health products has evolved from a product-specific framework into a more integrated, risk-based, lifecycle-oriented system. This evolution has strengthened regulatory predictability and enabled more efficient oversight across the product lifecycle.
The establishment of the Health Products (Therapeutic Products) Regulations 2016, which brought the regulation of pharmaceutical products under the Health Products Act, marked one key milestone. Consolidating registration, licensing, and supply-chain controls within a single legislative framework created a more integrated regulatory model and provided greater clarity across the product lifecycle.
As HSA’s regulatory approach has matured, assessment and oversight of pharmaceutical products have become progressively more risk-proportionate with continuous refinement of registration requirements to streamline processes, improve predictability, and clarify documentation expectations. One notable example was the expansion in 2022 of post-approval changes permitted under the MIV-2 “Do-and-Tell” notification pathway, following optimization of the variation checklist. This reform demonstrates HSA’s continued efforts to calibrate regulatory oversight according to product risk, reduce unnecessary regulatory burden, and support more efficient lifecycle management.
HSA has also developed fit-for-purpose regulatory frameworks and guidance for emerging technologies, including cell, tissue, and gene therapies, software as a medical device, digital health products, AI-related tools, and laboratory-developed tests (Table 1). These initiatives demonstrate HSA’s commitment to ensuring that regulatory requirements continue to evolve alongside scientific and technological advances.
